Advocacy intelligence hub — real-time data for patient organizations
Elahere: FDA approved
treatment of adult patients with folate receptor-alpha (FR?) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.
Hoffmann-La Roche — PHASE2
Rubraca: FDA approved
For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Lynparza: FDA approved
Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
Zejula: FDA approved
Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Gliadel: FDA approved
As an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Patient Assistance Programs2
Oncoscint CR/OV
Cytogen Corporation
Rubraca
pharma&
Elahere
(mirvetuximab soravtansine-gynx)Orphan drugImmunoGen, Inc.
12.1 Mechanism of Action Mirvetuximab soravtansine-gynx is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against folate r...
Rubraca
(rucaparib)Orphan drugpharma&
12.1 Mechanism of Action Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a ...
Lynparza
(olaparib)Orphan drugAstraZeneca Pharmaceuticals LP
Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
12.1 Mechanism of Action Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are ...
Zejula
(niraparib)Orphan drugGlaxoSmithKline, LLC.
12.1 Mechanism of Action Niraparib is an inhibitor of PARP enzymes, including PARP-1 and PARP-2, that play a role in DNA repair. In vitro studies have...
Gliadel
(polifeprosan 20 with carmustine)Orphan drugGuilford Pharmaceuticals, Inc.
Alkylating Drug [EPC]
12.1 Mechanism of Action The activity of GLIADEL Wafer is due to release of cytotoxic concentrations of carmustine, a DNA and RNA alkylating agent, in...
Doxil
(doxorubicin HCL liposome injection)Orphan drugstandardJohnson & Johnson Pharmaceutical Research & Dev.
12.1 Mechanism of Action The active ingredient of DOXIL liposomal infusion is doxorubicin hydrochloride. The mechanism of action of doxorubicin hydroc...
Oncoscint CR/OV
(Satumomab pendetide)Orphan drugstandardCytogen Corporation
Matthew Krebs, Dr
The Christie Hospital
Florence JOLY
Centre François Baclesse
Els Van Nieuwenhuysen, MD PhD
UZ Leuven
Sandip P Patel
SWOG Cancer Research Network
📍 Birmingham, Alabama
Camila MV Moniz, Doctor
Oncologist
📍 SAN ANTONIO, TX
Michael Heinrich, MD
Oregon Health and Science University